美国 · 平台与数据 · Benzinga
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

详细摘要
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home…
MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.benzinga.com)




